Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- RDNT +19.9%, ARMK +2.9%, PBI +2.9% (guidance), TXNM +1.6%, PK +0.8% (guidance)
Other news:
- CAN +18.3% (Canaan enters agreement with HIVE (HIVE) for Avalon A1566 Miners)
- EVO +17.4% (Triton Partners mulling bid for EVO, according to Bloomberg)
- NVX +16% (signs binding offtake agreement with Stellantis)
- HIVE +13.3% (Canaan enters agreement with HIVE (HIVE) for Avalon A1566 Miners)
- AUTL +9.4% (announces FDA approval of AUCATZYL (obecabtagene autoleucel -- obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia) SOUN +8.6% (entered into an Equity Distribution Agreement on Friday)
- PYXS +5.2% (to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201)
- SPRY +4.5% (signs agreement with ALK to Commercialize neffy in Europe, Canada and Other Geographies Outside the United States)
- APP +4.3% (AppLovin (APP) to join the Nasdaq-100 Index beginning November 18)
- IMCR +3.8% (prepaid in full the loan outstanding under the loan agreement)
- PTON +3.4% (provided litigation update on Friday)
- IDYA +3% (Biocytogen announces IDEAYA's nomination of development candidate IDE034, a potential first-in-class B7H3/PTK7 topo-i-payload bispecific ADC and option exercise)
- CHGG +2.9% (being impacted by artificial intelligence, according to WSJ)
- NWG +2.1% (buy's back GBP1.0 bln shares from government)
- IMMR +2% (declared a special cash dividend of $0.245 per share)
- TECX +1.9% (Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein)
- RARE +1.9% (Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit)
- CNC +1.6% (CEO disclosed the purchase of 4,117 shares at $60.80 - $60.81 worth approx. $250K)
- MODV +1.5% (Q Global Capital disclosed increased active stake of 12.69% (previously 10.53% passive stake))
- SWTX +1.5% (Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology)
- TS +1.2% (to commence a $700 mln share buyback program)
- SSSS +1% (amended on Friday its At-the-Market Sales Agreement)